Combined chemo- and immunotherapy of tumors induced in mice by bcr-abl-transformed cells

Oncology Reports

Volumn 21, Issue 3, 2009, Pages 793-799

  Sobotkova, Eva ^a   Duskova, Martina ^a   Tachezy, Ruth ^a   Petrackova, Martina ^a   Vonka, Vladimir ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Cell vaccines; Chronic myeloid leukemia; Cyclophosphamide; Imatinib mesylate; Interferon ; Mouse bcr abl transformed cells

Indexed keywords

BCR ABL PROTEIN; CYCLOPHOSPHAMIDE; CYTOKINE; IMATINIB; RECOMBINANT ALPHA INTERFERON; TUMOR CELL VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SOLID TUMOR; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CELL LINE, TRANSFORMED; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; FUSION PROTEINS, BCR-ABL; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-2; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; PIPERAZINES; POLYMERASE CHAIN REACTION; PYRIMIDINES;

EID: 64849100156     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000286     Document Type: Article

References (53)

1. bcr/abl gene of the Philadelphia chromosome. Science 247: 824-830, 1990.
2. Kelliher MA, McLaughlin J, Witte ON and Rosenberg N: Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ ABL. Proc Natl Acad Sci USA 87: 6649-6653, 1990.
3. Wong S and Witte ON: The BCR-ABL story: bench to bedside and back. Annu Rev Immunol 22: 247-306, 2004.
4. Buchdunger E, Zimmermann J, Mett H, Meyer T, Müller M, Druker BJ and Lydon NB: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56: 100-104, 1996.
5. Druker BJ, Tamura S, Buchdunger E, et al: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561-566, 1996.
6. + leukemic cells and induces apoptosis. Blood Cells Mol Dis 23: 380-394, 1997.
7. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B and Kuriyan J: Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289: 1938-1942, 2000.
8. Deininger MW, Goldman JM, Lydon N and Melo JV: The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90: 3691-3698, 1997.
9. le Coutre P, Mologni L, Cleris L, et al: In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 91: 163-168, 1999.
10. Sobotkova E, Ludvikova V, Petrackova M, et al: Characteristic of two mouse bcr-abl-transformed cell lines: I. General properties of the cells. Folia Biol (Praha) 51: 12-18, 2005.
11. Frame D: New strategies in controlling drug resistence. J Manag Care Pharm 13: 13-17, 2007.
12. Fausel C: Targeted chronic myeloid leukemia therapy: seeking a cure. Suppl J Manag Care Pharm 13: S8-S12, 2007.
13. Moen MD, McKeage K, Plosker GL and Siddiqui MA: Imatinib: a review of its use in chronic myeloid leukaemia. Drugs 67: 299-320, 2007.
14. Druker BJ, O'Brien SG, Cortes J and Radich J: Chronic myelogenous leukemia. Hematology (Am Soc Hematol Educ Program), pp111-135, 2002.
15. Daley GQ: Towards combination target-directed chemotherapy for chronic myeloid leukemia: role of farnesyl transferase inhibitors. Semin Hematol 40: 11-14, 2003.
16. Buchdunger E: Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia. Med Klin (Munich) 97: 2-6, 2002.
17. Nimmanapalli R and Bhalla K: Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias. Curr Opin Oncol 14: 616-620, 2002.
18. Bartolovic K, Balabanov S, Hartmann U, et al: Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood 103: 523-529, 2004.
19. + regulatory T cells in a dose-dependent manner. Int J Oncol 31: 1133-1139, 2007.
20. Chen CI, Maecker HT and Lee PP: Development and dynamics of robust T-cell responses to CML under imatinib treatment. Blood 111: 5342-5349, 2008.
21. Burchert A, Wölfl S, Schmidt M, et al: Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 101: 259-264, 2003.
22. bcr/abl protein. Proc Natl Acad Sci USA 85: 9312-9316, 1988.
23. Deng M and Daley GQ: Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukaemia. Blood 97: 3491-3497, 2001.
24. Thiesing JT, Ohno-Jones S, Kolibaba KS and Druker BJ: Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-ablpositive cells. Blood 96: 3195-3199, 2000.
25. Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y and Furukawa Y: In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 97: 1999-2007, 2001.
26. Marley SB, Davidson RJ, Goldman JM and Gordon MY: Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia. Br J Haematol 116: 162-165, 2002.
27. Bass KK and Mastrangelo MJ: Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol Immunother 47: 1-12, 1998.
28. Motoyoshi Y, Kaminoda K, Saitoh O, et al: Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol Rep 16: 141-146, 2006.
29. + T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J Immunother 30: 40-53, 2007.
30. Taieb J, Chaput N, Schartz N, et al: Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immunol 176: 2722-2729, 2006.
31. McLaughlin J, Chianese E and Witte ON: In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci USA 84: 6558-6562, 1987.
32. Jelínek F, Sobotková E and Vonka V: Characteristic of two mouse bcr-abl-transformed cell lines. II. Pathological lesion induced in mice. Folia Biol (Praha) 51: 93-102, 2005.
33. Ludvíková V, Hamsíková E, Sobotková E, Lucansky V, Smahel M and Vonka V: Use of polyclonal rabbit antibodies for detection of the bcr-abl fusion zone in cells transfected with experimental bcr-abl DNA vaccines. Int J Oncol 27: 265-274, 2005.
34. O'Brien S, Giles F, Talpaz M, et al: Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer 98: 888-893, 2003.
35. Kantarjian HM, O'Brien S, Cortes J, et al: Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer 98: 2636-2642, 2003.
36. Druker BJ: Imatinib alone and in combination for chronic myeloid leukemia. Semin Hematol 40: 50-58, 2003.
37. Paquette RL, Hsu N, Said J, et al: Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo. Leukemia 16: 1484-1489, 2002.
38. Burchert A and Neubauer A: Interferon alpha and T-cell responses in chronic myeloid leukemia. Leuk Lymphoma 46: 167-175, 2005.
39. Bracci L, Proietti E and Belardelli F: IFN-alpha and novel strategies of combination therapy for cancer. Ann NY Acad Sci 1112: 256-268, 2007.
40. + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 34: 36-44, 2004.
41. + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56: 641-648, 2007.
42. Mitchell MS: Immunotherapy as part of combinations for the treatment of cancer. Int Immunopharmacol 3: 1051-1059, 2003.
43. Bracci L, Moschella F, Sestili PI, et al: Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res 13: 644-653, 2007.
44. Nowak AK, Lake RA and Robinson BW: Combined chemoimmunotherapy of solid tumours: improving vaccines? Adv Drug Deliv Rev 58: 975-990, 2006.
45. Sobotková E, Dusková M, Smahel M, Holán V, Janousková O and Vonka V: Chemotherapy and immunotherapy of tumours induced by gene-modified HPV16-transformed cells. Oncol Rep 12: 877-883, 2004.
46. He L, Feng H, Raymond A, et al: Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice. Cancer Immunol Immunother 50: 31-40, 2001.
47. Zeng Y, Graner MW, Feng H, Li G and Katsanis E: Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukemia. Int J Cancer 110: 251-259, 2004.
48. + tumor cells. Blood 105: 2016-2022, 2005.
49. Kislin KL, Marron MT, Li G, Graner MW and Katsanis E: Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia. FASEB J 21: 2173-2184, 2007.
50. Gaiger A, Reese V, Disis ML and Cheever MA: Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood 96: 1480-1489, 2000.
51. Ohminami H, Yasukawa M and Fujita S: HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 95: 286-293, 2000.
52. Oka Y, Tsuboi A, Elisseeva OA, Udaka K and Sugiyama H: WT1 as a novel target antigen for cancer immunotherapy. Curr Cancer Drug Targets 2: 45-54, 2002.
53. Scheibenbogen C, Letsch A, Thiel E, et al: CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 100: 2132-2137, 2002.